FDA & Government News

Cataract Surgeons Gain a New Lens Tool

An extended depth of focus intraocular lens approved by the FDA is designed to improve visual range while maintaining contrast sensitivity in cataract surgery.

Share

The FDA has approved the TECNIS PureSee intraocular lens (IOL) for cataract surgery, a device designed to combat vision loss associated with cataracts and presbyopia. As patients age, cataracts can impair essential activities such as reading and driving. This extended depth of focus IOL aims to facilitate improved distance and intermediate vision, while offering some near vision capabilities. Notably, it is the first approved IOL in the US without warnings concerning loss of contrast sensitivity, proving effective in clinical evaluations. The lens is slated for US availability in 2026.

Original Source(s)

Cataract Surgeons Gain a New Lens Tool

An extended depth of focus intraocular lens approved by the FDA is designed to improve visual range while maintaining contrast sensitivity in cataract surgery.

  • by Kathryn Wighton

  • March 12, 2026

  • 3 min

Related Content

Beyond IOP: The Mood Effects of CAIs

Evidence from large US dataset suggests topical carbonic Anhydrase Inhibitors may increase depression risk in glaucoma patients

  • March 12, 2026

  • 5 min
The Most Influential Conversations in Ophthalmology Aren’t on the Podium

How WhatsApp is quietly shaping clinical practice

Could Wegovy Raise Optic Nerve Risk?

A pharmacovigilance analysis of FDA adverse event reports finds the strongest ischemic optic neuropathy reporting signal with high-dose semaglutide formulations, with higher adjusted odds reported in men.